The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL – Results From the Phase-II STORM Trial

There is a high need for novel treatment options in relapsed and refractory diffuse large B-cell lymphoma. Single agent mammalian target of rapamycin (mTOR) inhibitor treatment has shown promising efficacy in this entity. Here, we report on the results of the mTOR-inhibitor temsirolimus combined to...

Descripción completa

Detalles Bibliográficos
Autores principales: Witzens-Harig, Mathias, Viardot, Andreas, Keller, Ulrich, Wosniok, Julia, Deuster, Oliver, Klemmer, Jennifer, Geueke, Anne-Marie, Meißner, Julia, Ho, Anthony D., Atta, Johannes, Marks, Reinhard, La Rosée, Paul, Buske, Christian, Dreyling, Martin H., Hess, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476051/
https://www.ncbi.nlm.nih.gov/pubmed/34589671
http://dx.doi.org/10.1097/HS9.0000000000000636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476051/
https://www.ncbi.nlm.nih.gov/pubmed/34589671
http://dx.doi.org/10.1097/HS9.0000000000000636

Ejemplares similares